Study compares the performance of two most popular AMD drugs

A pilot, "look-back" study of information about 106 patients with "wet" age-related macular degeneration (AMD) treated at the Wilmer Eye Institute at Johns Hopkins Medicine has revealed that nearly half of patients treated with aflibercept could safely stop eye injection therapy after one year without further vision loss.

Related Keywords

United States , Johns Hopkins University , Maryland , University Of Maryland , Akrit Sodhi , Silvia Montaner , Danyal Malik , Tapan Patel , Anuoluwapo Sopeyin , Emily Henderson , Chuanyu Guo , Xuan Cao , Johns Hopkins , Jaron Castillo Sanchez , Zhiyong Yang , Lab Diagnostics Automation , Johns Hopkins University School Of Medicine , Lab Diagnostics Automation Industry , Wilmer Eye Institute At Johns Hopkins Medicine , Wilmer Eye Institute , Johns Hopkins Wilmer Eye Institute , Johns Hopkins Medicine , Associate Professor , Irving Sisenwein Professor , Johns Hopkins University School , Automation Industry Focus , Drugs , Macular Degeneration , Age Related Macular Degeneration , Evacizumab , Flood , Blood Vessels , Eye , Medicine , Ophthalmology , Mh , Vision Loss ,